Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

People on First HIV Protease Inhibitor May Not Need to Switch After Single Treatment Failure

People with HIV who experience a single episode of virological failure while on their first protease inhibitor can safely stay on the same regimen without risk of disease progression, according to a study described in the May 19, advance edition of Clinical Infectious Diseases.

alt

Read more:

Efavirenz Linked to Higher Suicide Risk, May Be Falling Out of Favor

The widely used NNRTI efavirenz was associated with a 2-fold increase in the likelihood of suicidal thoughts, attempted suicides, and suicide deaths, though the absolute risk remained small, according to a study described in the July 1 Annals of Internal Medicine. A related review article questioned whether efavirenz should still be considered a preferred option for initial HIV treatment, given its side effects and the development of equally effective and better-tolerated alternatives.

alt

Read more:

BMS Licenses Atazanavir to Medicines Patent Pool, Allowing Cheaper Generics

Bristol-Myers Squibb and the Medicines Patent Pool have reached a licensing agreement that will enable generic drug manufacturers to produce inexpensive versions of the HIV protease inhibitor atazanavir (Reyataz), as well as fixed-dose combinations containing the drug, for use in low-income countries, MPP recently announced. It is the first MPP agreement to cover a preferred second-line therapy.

alt

Read more:

Clinical Trial of Once-Daily Raltegravir Now Underway

Merck announced this week that treatment-naive participants are now being enrolled in the Phase 3 ONCEMRK trial, which is evaluating the efficacy and safety of a ne formulation of the HIV integrase inhibitor raltegravir (Isentress) taken once rather than twice daily.

alt

Read more:

HIV Integrase Inhibitor Elvitegravir Approved in European Union

The next-generation HIV integrase inhibitor elvitegravir has been approved by the European Commission, to be marketed under the brand name Vitekta, according to an announcement this week from developer Gilead Sciences. It is indicated for use in combination antiretriviral regimens containing a ritonavir-boosted protease inhibitor.

alt

Read more: